Diamyd Medical’s diabetes vaccine and regenerative medicine in synergy

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) is the largest shareholder in Cellaviva AB, which is Sweden’s first biobank for private family preservation of, and research on, stem cells from the umbilical cord. In conjunction with the election of Anders Essen-Möller, Diamyd Medical’s principal owner, as the new Chairman of the Board for Cellaviva, clarification is provided herein of Diamyd Medical’s views on the synergies between the companies.Diamyd Medical is dedicated to finding a cure for type 1 diabetes. The strategy is in part to use Antigen Based Therapy (ABT), such as the